Beximco PharmaceuticalsLSE:BXP 71 Gross Margin % is 49.14% as of Mar. 2026, which is 6% above its 10-year median of 46.33. GuruFocus rates LSE:BXP with a GF Score™ of 71/100 and a GF Value™ of £0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 936 Drug Manufacturers companies, Beximco Pharmaceuticals ranks worse than 51.6% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Beximco Pharmaceuticals had a gross margin of 49.14% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Beximco Pharmaceuticals Gross Margin % Related Terms
Beximco Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Beximco Pharmaceuticals (LSE:BXP) has a Gross Margin % of 49.14% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Beximco Pharmaceuticals and its competitors. This is near median its historical median of 46.33. Over the past decade, Beximco Pharmaceuticals' Gross Margin % has ranged from 44.07 to 47.86. According to the industry distribution chart, Beximco Pharmaceuticals ranks #483 out of 936 companies in the Drug Manufacturers industry, placing it in the top 51.6%.
Is Beximco Pharmaceuticals' Gross Margin % too high?
Beximco Pharmaceuticals' current Gross Margin % of 49.14% is near median its 10-year median of 46.33. Over the past 10 years, this metric has ranged from a low of 44.07 to a high of 47.86. The Drug Manufacturers industry median Gross Margin % is 48.50. Beximco Pharmaceuticals' value of 49.14% is 1.3% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #483 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #483 out of 936 companies for Gross Margin %. This places Beximco Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.50. Beximco Pharmaceuticals' value of 49.14% is 1.3% above this benchmark. Historically, Beximco Pharmaceuticals' own Gross Margin % has ranged from 44.07 to 47.86 over the past decade. While the company's 10-year median is 46.33 vs. the industry median of 48.50, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Gross Margin % of 49.14% is 1.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Gross Margin % is 49.14%, which is near median its own 10-year median of 46.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.45, compared to a current price of £0.50 — trading 11.1% above its estimated fair value. The current Gross Margin % is 49.14%, which is near median its 10-year median of 46.33 and 1.3% above the Drug Manufacturers industry median of 48.50. Beximco Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Gross Margin % is 49.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?
Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued.
The current stock price of £0.50 is trading 11.1% above its estimated GF Value™ of £0.45.
GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LSE:BXP:
Gross Margin %: 49.14% (near median its 10-year median of 46.33)
GF Value™: £0.45 vs. price of £0.50 (11.1% above fair value)
Industry Position: 1.3% above the Drug Manufacturers median (#483 of 936)
No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
71GF Score
Get the complete analysis for LSE:BXP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BXP has been successfully added to your 
